RxDoctor Payments DataLook up a doctor →

Reynolds Delgado, MD

Cardiovascular Disease · Houston, TXNPI 1720024466

Payments from drug & device makers

$1,089,046in general payments, 2019–2025

Across 1,382 payments — averaging $788.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procyrion, Inc.$462K
  • American Regent$157K
  • Boehringer Ingelheim$150K
  • Akcea Therapeutics, Inc.$70K
  • Merck$49K
  • AstraZeneca$49K
  • plus $152K from 50 others
$700in research payments, 2019–2025

Across 1 payment — averaging $700.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Adagio Medical, Inc.$700

What the payments were for

  • Consulting fees$12,8283%
  • Speaking & faculty fees$386,17982%
  • Travel & lodging$42,4529%
  • Food & beverage$28,9356%
  • Education$1520%
  • Entertainment$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,089,046 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$482,459
Medicare patients
344
Services billed
6,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis22$497,541
VyndaqelTafamidis Meglumine11$245,655
EliquisApixaban159$180,566
JardianceEmpagliflozin147$162,892
EntrestoSacubitril/Valsartan105$148,512
CamzyosMavacamten12$99,112
XareltoRivaroxaban80$81,628
FarxigaDapagliflozin Propanediol47$61,870
VerquvoVericiguat23$34,807
Repatha SureclickEvolocumab30$31,078
KerendiaFinerenone29$28,484
Tacrolimus62$13,015
Metoprolol Succinate655$11,940
Sirolimus16$9,990
Atovaquone14$8,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$30,257$923,762192 claims
Boehringer IngelheimJardiance$150,387$162,892147 claims
NovartisEntresto$15,241$148,512105 claims
E.r. Squibb & Sons, L.L.C.Camzyos$1,049$99,11212 claims
Johnson & JohnsonXarelto$35,127$81,62880 claims
AstraZenecaFarxiga, Brilinta$48,524$69,23163 claims
MerckVerquvo$48,941$34,80723 claims
BayerKerendia$14,504$28,48429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →